MANF Inhibits α-Synuclein Accumulation through Activation of Autophagic Pathways

Oxid Med Cell Longev. 2022 Jul 8:2022:7925686. doi: 10.1155/2022/7925686. eCollection 2022.

Abstract

Progressive accumulation of misfolded SNCA/α-synuclein is key to the pathology of Parkinson's disease (PD). Drugs aiming at degrading SNCA may be an efficient therapeutic strategy for PD. Our previous study showed that mesencephalic astrocyte-derived neurotrophic factor (MANF) facilitated the removal of misfolded SNCA and rescued dopaminergic (DA) neurons, but the underlying mechanisms remain unknown. In this study, we showed that AAV8-MANF relieved Parkinsonian behavior in rotenone-induced PD model and reduced SNCA accumulation in the substantia nigra. By establishing wildtype (WT) SNCA overexpression cellular model, we found that chaperone-mediated-autophagy (CMA) and macroautophagy were both participated in MANF-mediated degradation of SNCAWT. Nuclear factor erythroid 2-related factor (Nrf2) was activated to stimulating macroautophagy activity when CMA pathway was impaired. Using A53T mutant SNCA overexpression cellular model to mimic CMA dysfunction situation, we concluded that macroautophagy rather than CMA was responsible to the degradation of SNCAA53T, and this degradation was mediated by Nrf2 activation. Hence, our findings suggested that MANF has potential therapeutic value for PD. Nrf2 and its role in MANF-mediated degradation may provide new sights that target degradation pathways to counteract SNCA pathology in PD.

MeSH terms

  • Autophagy / physiology
  • Dopaminergic Neurons / metabolism
  • Humans
  • NF-E2-Related Factor 2 / metabolism
  • Nerve Growth Factors / metabolism
  • Parkinson Disease* / drug therapy
  • alpha-Synuclein* / genetics
  • alpha-Synuclein* / metabolism

Substances

  • MANF protein, human
  • NF-E2-Related Factor 2
  • Nerve Growth Factors
  • alpha-Synuclein